Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography

被引:13
作者
Benatar, A
Feenstra, A
Decraene, T
Vandenplas, Y
机构
[1] Free Univ Brussels, Acad Hosp, Dept Pediat Cardiol, B-1090 Brussels, Belgium
[2] Free Univ Brussels, Acad Hosp, Dept Pediat Gastroenterol, B-1090 Brussels, Belgium
关键词
QT interval; QTc; cisapride; heart rate; heart rhythm; infants;
D O I
10.1542/peds.106.6.e85
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. To evaluate the effects of cisapride, a prokinetic gastrointestinal drug, on the electrocardiographic QT interval, heart rate, and rhythm in infants during routine 8-hour polysomnography. Reported electrocardiogram (ECG) and rhythm disturbances in a small number of patients with the use of cisapride provided the impetus for this prospective study. Study Design. Two hundred fifty-two infants born at term were enrolled. Of these, 134 were on cisapride therapy for suspected gastroesophageal reflux and 118 were not on cisapride and served as controls. Cisapride-treated and control infants were from the outset divided into 3 age groups; group 1: under 3 months of age; group 2: between 3 and 6 months of age; and group 3: >6 months of age. Continuous ECG bipolar limb lead I recording, saturation monitoring, and electroencephalography were conducted. QT intervals and heart rate were measured at hourly intervals. Results. Cisapride doses were: group 1 mean, 0.80 mg/kg/day (range: 0.38-1.55); group 2 mean, 0.80 mg/kg/ day (range: 0.23-1.38); and group 3 mean, 0.72 mg/kg/ day (range: 0.32-1.41). Heart rate was higher in the younger infants, with a gradual decrease with age. No difference in heart rate was detected between the cisapride and control groups. The QTc interval in patients in group 1 was statistically longer than the controls, when applying both Bazett's and Hodges' formulae for QT correction. The other age groups did not differ. No arrhythmia or atrioventricular conduction abnormalities were observed. Conclusion. Infants under 3 months of age on cisapride treatment had significantly longer QTc intervals (with Bazett's formula, the 98th percentile was 504 ms in the cisapride group vs 447 ms in controls). The clinical significance and risk of the increased QTc interval in these infants are unclear and need further evaluation and risk stratification. Meanwhile, cisapride should be judiciously prescribed in infants <3 months of age.
引用
收藏
页码:art. no. / e85
页数:5
相关论文
共 38 条
  • [1] CISAPRIDE AND TORSADES-DE-POINTES
    AHMAD, SR
    WOLFE, SM
    [J]. LANCET, 1995, 345 (8948): : 508 - 508
  • [2] POSTNATAL-DEVELOPMENT OF RENAL-FUNCTION DURING THE 1ST YEAR OF LIFE
    ARANT, BS
    [J]. PEDIATRIC NEPHROLOGY, 1987, 1 (03) : 308 - 313
  • [3] Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
  • [4] Effects of cisapride on QTc interval in neonates
    Bernardini, S
    Semama, DS
    Huet, F
    Sgro, C
    Gouyon, JB
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 1997, 77 (03): : F241 - F243
  • [5] LONG QT SYNDROME DURING HIGH-DOSE CISAPRIDE
    BRAN, S
    MURRAY, WA
    HIRSCH, IB
    PALMER, JP
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (07) : 765 - 768
  • [6] Carlsson L, 1997, J PHARMACOL EXP THER, V282, P220
  • [7] NORMAL ECG STANDARDS FOR INFANTS AND CHILDREN
    DAVIGNON, A
    RAUTAHARJU, P
    BOISSELLE, E
    SOUMIS, F
    MEGELAS, M
    CHOQUETTE, A
    [J]. PEDIATRIC CARDIOLOGY, 1980, 1 (02) : 123 - 131
  • [8] Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval
    Drolet, B
    Khalifa, M
    Daleau, P
    Hamelin, BA
    Turgeon, J
    [J]. CIRCULATION, 1998, 97 (02) : 204 - 210
  • [9] UTILITY OF QT DISPERSION COMBINED WITH THE SIGNAL-AVERAGED ELECTROCARDIOGRAM IN DETECTING PATIENTS SUSCEPTIBLE TO VENTRICULAR TACHYARRHYTHMIA
    GOLDNER, B
    BRANDSPIEGEL, HZ
    HORWITZ, L
    JADONATH, R
    COHEN, TJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (16) : 1192 - &
  • [10] Cisapride (CIS) biotransformation: Not all CYP3AS are created equal.
    Gotschall, RR
    Marcucci, K
    Leeder, JS
    Kearns, GL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 127 - 127